• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News Translations

I alle Norges hjem og hjerter: DNDi og Leger Uten Grenser er tildelt TV-aksjonen 2022, Norges største innsamlingsaksjon

Home > News Translations

I alle Norges hjem og hjerter: DNDi og Leger Uten Grenser er tildelt TV-aksjonen 2022, Norges største innsamlingsaksjon

Children holing donation mug for the TV-Aksjonen
23 Sep 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • Norsk
    • English
    • Norsk

I 1999 ble Leger Uten Grenser tildelt Nobels Fredspris. Da Leger Uten Grenser fikk fredsprisen ble det besluttet at deler av pengene skulle brukes til å opprette en ny “non-profit”-modell for å utvikle medisiner til neglisjerte pasienter. Dette ble starten på Drugs for Neglected Diseases Initative (DNDi). 23 år senere vil nok en stor begivenhet for vår organisasjon finne sted i landet.   

TV-aksjonen – en av verdens største innsamlingsaksjoner

Målet er at 100.000 frivillige skal besøke alle husstander i Norge i løpet av to timer søndag 23. oktober. De frivillige skal samle inn donasjoner med bøsser, og lokale arrangementer blir også arrangert – alt for å støtte arbeidet til Leger Uten Grenser og DNDi.

Samtidig skal nærmere én halv million barn lære om neglisjerte sykdommer gjennom et skreddersydd skoleprosjekt, som tilbys gratis til de mellom 6 og 15 år. Dette er en del av den store årlige innsamlingsaksjonen som heter TV-aksjonen. TV-aksjonen har blitt arrangert av den norske allmennkringkasteren NRK siden 1974. Det er regnet som verdens største innsamlingsaksjon målt i antall frivillige og innsamlede midler per hode.

Vi er utrolig stolte over å ha blitt tildelt TV-aksjonen 2022 sammen med Leger Uten Grenser. Slagordet er: «Sammen redder vi liv». Tidligere TV-aksjoner har gått til blant annet Røde Kors, Flyktninghjelpen, Unicef, WWF og Amnesty International.

The MSF team celebrating their selection as one of the beneficiaries of the 2022 edition of of TV-Aksjonen

Glemt av legemiddelindustrien: Når medisiner som er nødvendig for å kurere millioner av mennesker ikke engang eksisterer

På 80- og 90-tallet møtte leger fra Leger Uten Grenser, som bistod mennesker rammet av konflikt og katastrofer, pasienter som led av neglisjerte sykdommer som sovesyke og kala-azar. Dette var sykdommer de ikke hadde medisiner mot. Medisinene som eksisterte  var giftige, utilgjengelige eller for dyre. Mange av disse sykdommene kan være dødelige uten behandling. Men da de stort sett rammer fattige lokalsamfunn, har ikke den tradisjonelle legemiddelindustrien noe økonomisk insentiv til å utvikle legemidler mot sykdommene.

Ideen om DNDi ble skapt ut av frustrasjonen legene i Leger Uten Grenser, samt forskere i landene som var rammet av neglisjerte sykdommer, følte på da de stod ansikt til ansikt med mangelen på medisiner og urettferdigheten som rammet de mest sårbare.Leger Uten Grenserdedikerte en del av midlene de mottok etter å ha fått Nobels fredspris, til å ta tak i denne alvorlige urettferdigheten, og gikk inn i et samarbeid med Verdens helseorganisasjon og ledende medisinske institutter i Brasil, Frankrike, India, Kenya og Malaysia. Dette ledet til at DNDi ble opprettet i 2003 -en ideell organisasjon som hadde som oppdrag å utvikle legemidler for neglisjerte pasienter.

Siden 2003 har DNDi utviklet tolv nye behandlinger mot seks dødelige sykdommer, og med dette reddet millioner av liv.

Finansiering av forskning på to dødelige og neglisjerte sykdommer

Midlene som samles inn gjennom TV-aksjonen 2022 skal gå til Leger Uten Grensers arbeid med dødelige sykdommer i fire land: Den demokratiske republikken Kongo, Sierra Leone, Den sentralafrikanske republikk og Bangladesh. Deler av midlene skal også gå til å finansiere DNDis arbeid med å utvikle nye, trygge og billige legemidler mot sovesyke og kala-azar.

Til tross for enkelte forbedringer i behandlingene, rammer disse dødelige og neglisjerte sykdommene fortsatt millioner av mennesker, spesielt i Latin-Amerika, Afrika og Sør-Asia. Leger har fortsatt ikke tilstrekkelig med medisiner for å kunne behandle pasientene sine. Men med din støtte forsker teamene våre på hvordan man kan gjøre eksisterende behandlinger bedre, samt utvikle nye behandlinger mot neglisjerte sykdommer.

Vi vil gjerne uttrykke vår dypeste takknemlighet til de tusenvis av frivillige, og millionene av givere i Norge, for den enestående solidariteten de viser gjennom årets TV-aksjon. Takk for at du hjelper oss med å bringe den beste vitenskapen til de mest neglisjerte!

More information

  • TV-aksjonen website

Photo credits: Mikkel Strøm/TV-aksjonen; Marion Mossing / MSF; Alexis Huguet; Xavier Vahed-DNDi

Funding Norway

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo